News

Bonumose’s Low-Cost Tagatose Process Receives Key Health Agency Approvals; Construction of First Production Facility on Schedule for Spring 2022 Opening

ASR Group – exclusive sales and distribution partner – reports strong customer demand for the unique, rare sugar, accelerating the timeline for a second production plant.
Bonumose, Inc. announces the achievement of regulatory and food application milestones in the United States and Canada for the low-glycemic, rare sugar tagatose, as the company progresses on time and on schedule for the opening of its first commercial production facility in Spring 2022.
“A low-cost tagatose supply is highly sought after by leading, global food companies for a wide variety of applications that meet sugar-reduction targets in confectionery, ready-to-eat cereal, ice cream, yogurt, beverages, meal replacement drinks, cookies, bars and other popular categories,” said Ed Rogers, CEO of Bonumose. “Tagatose’s unique features enable it to meet calorie-reduction targets without compromising taste or texture while working within companies’ existing food production lines.”

Tagatose – a rare sugar that occurs in tiny quantities in some fruits and grains as well as in the cocoa tree – is 92% as sweet as sugar, maintains a clean, no-aftertaste flavor profile as well as provides critical functionality such as bulking, mouthfeel, caramelization, freezing-point depression and low hygroscopicity. Tagatose has a negligible glycemic index (3), 60 percent fewer calories than sucrose and prebiotic, fiber-like benefits by feeding healthy probiotics in the gut.

To date, the obstacle limiting widespread use of tagatose has been its high cost. Bonumose solves the issue through a lower-cost method using non-dairy, plant-based starch, enzymes and a streamlined process that eliminates several complicated steps that inflate the cost of tagatose and allulose for other producers.

The U.S. Food and Drug Administration (FDA) recently approved Bonumose’s unique method. Additionally, Health Canada approved Bonumose’s process, marking the first time tagatose has been approved for sale in Canada. Regulatory submissions are underway and planned in all major markets worldwide.

Bonumose will launch tagatose production and sales in the first half 2022 with ASR Group, the world’s largest cane sugar refiner and marketer. ASR Group is Bonumose’s exclusive distribution partner in the United States, Canada, Mexico and Western Europe. ASR Group’s customers have successfully tested tagatose in formulations to meet reduction targets without sacrificing taste or function.

“Tagatose has performed extremely well for our customers across a wide variety of applications, and they are enthusiastic about having an affordable supply of tagatose available to them soon,” said Jim Kappas, ASR Group’s Vice President of Specialty Ingredients. “Using these insights, we forecast demand may already outstrip the production capacity at Bonumose’s first production plant, and we will likely need to scale up as soon as possible.”

Recent News

12/05/2022

Danville organization invests in Blacksburg’s CytoRecovery medical cell sorting company

Danville’s investment might mean a CytoRecovery presence in Danville, such as office operations or an internship at Danville Community College. CytoRecovery’s cell sorting could improve understanding of disease and development of drugs. CytoRecovery, an early-stage company that invented and patented less invasive cell sorting, will be able to bring its cell research platform to market

12/01/2022

Ceres Nanosciences Receives $1.4M From NIH RADx Initiative to Add Five Additional Wastewater-Based Epidemiology Centers of Excellence

MANASSAS, Virginia – Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing today that it is expanding the network of wastewater-based epidemiology centers of excellence that was established with support from the National Institutes of Health (NIH) RADx® initiative. With a new $1.4

11/16/2022

Alliance for Building Better Medicine Names Joy Polefrone as Executive Director

Joy Polefrone, Ph.D. will Lead the Organization in Its Mission to Create a Reliable Supply of Safe, High-Quality, and Affordable Medicines in the U.S. Richmond/Petersburg– Alliance for Building Better Medicine, a coalition of public and private sector stakeholders in the Richmond-Petersburg region, today announced that it has appointed Joy Marie Polefrone, Ph.D., as the organization’s executive director.